You are here

Article info

Article menu

Download PDFPDF

Connective tissue diseases
Original research
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies

Authors

  • Manuel Graf Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Sae Lim von Stuckrad Department of Pediatric Pneumology, Immunology and Critical Care Medicine and SPZ (Center for Chronically Sick Children), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Akinori Uruha Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Jens Klotsche German Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany PubMed articlesGoogle scholar articles
  • Lydia Zorn-Pauly Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Nadine Unterwalder Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany PubMed articlesGoogle scholar articles
  • Thomas Buttgereit Department of Dermatology and Allergy, Dermatological Allergology, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Martin Krusche Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Christian Meisel Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany PubMed articlesGoogle scholar articles
  • Gerd R Burmester Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Falk Hiepe Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Robert Biesen Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Tilmann Kallinich Department of Pediatric Pneumology, Immunology and Critical Care Medicine and SPZ (Center for Chronically Sick Children), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany PubMed articlesGoogle scholar articles
  • Werner Stenzel Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Udo Schneider Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Thomas Rose Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Thomas Rose; thomas.rose{at}charite.de
View Full Text

Citation

Graf M, von Stuckrad SL, Uruha A, et al
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies
RMD Open 2022;8:e001934. doi: 10.1136/rmdopen-2021-001934

Publication history

  • Received September 13, 2021
  • Accepted January 23, 2022
  • First published February 17, 2022.
Online issue publication 
June 08, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.